Background: The EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event
Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium-glucose …

Aims Empagliflozin reduced the risk of cardiovascular (CV) death and heart failure (HF)
hospitalizations in patients with type 2 diabetes (T2D) and established CV disease (CVD) in …

Background: Sodium-glucose cotransporter 2 inhibitors improve outcomes in patients with
heart failure with reduced ejection fraction, but additional information is needed about …

Aims We previously reported that in the EMPA-REG OUTCOME® trial, empagliflozin added
to standard of care reduced the risk of 3-point major adverse cardiovascular events …

Background Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, but their effects in …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure in patients regardless of the presence or absence of …

Background: In the EMPA-REG OUTCOME trial (BI 10773 [Empagliflozin] Cardiovascular
Outcome Event Trial in Type 2 Diabetes Mellitus Patients) in patients with type 2 diabetes …

Aim To investigate effectiveness and safety outcomes among patients with type 2 diabetes
(T2D) initiating empagliflozin versus dipeptidyl peptidase‐4 (DPP‐4) inhibitor treatment …

Importance Albuminuria, routinely assessed as spot urine albumin-to-creatinine ratio
(UACR), indicates structural damage of the glomerular filtration barrier and is associated …

BACKGROUND: It is not known whether the benefits of sodium-glucose cotransporter 2
inhibitors in heart failure persist after years of therapy. METHODS: In the EMPEROR …